Diego Di Leva
Vice President Global Partnerships
Originally from Italy, Diego Di Leva is the VP of Global Language Resources. In this role, Diego leads teams responsible for executing end-to-end project management and supply chain strategy.
He joined CSOFT as an Italian QA Specialist/Translator, position that he covered for five years after which he has started to cover more managerial and operational roles. Prior to joining CSOFT, Diego worked as a Tech Consultant for two years at a leading global mobile company.
SVP, Strategic Partnerships & Medical Writing
Dr. Nimita has held executive leadership positions, working across global pharma’s, CROs and consulting companies including Altana Pharma, Siro Clinpharm, Quintiles (now IQVIA), Tata Consultancy Services, and Applied Technology Solutions Inc. USA, and has been an entrepreneur, as well as a strategic advisor and mentor for start-ups in life sciences.
She has served as an industry thought leader, presented at global leadership forums, chaired the SCDM board, given keynote talks (including at DIA) and has interfaced with global pharmaceutical and medical leaders. She has rich experience leading clinical data management (CDM), risk-based monitoring (RBM) and medical writing operations, and has recently joined CSOFT Health Sciences Boston as the SVP, Strategic Partnerships & Medical Writing.
Senior Practice Lead & Executive Director, CSOFT Health Sciences
Di Lv has worked in the international healthcare market for the past 8 years. With a deep understanding of China’s healthcare and regulations, Di received her first law degree in China and then pursued further studies in the UK obtaining a second law degree with a focus in human rights.
Entering the healthcare market in 2010, Di first worked for BGI (Beijing Genomics Institute), one of the largest biotechnology firms in China. Her work at BGI took her to Belgium and Germany as the Business Development Manager, calling on clinical institutions, medical schools, and pharmaceutical companies.
Chief Strategist, China Market Access
With more than 14 years of experience working with international pharmaceutical programs in anti-infective, cardiovascular, endocrine, and nutritional products at companies including Xi‘an Janssen, Novartis Pharmaceuticals, and Mead Johnson (China), Dr. Wang has participated in Asian market registration, clinical research, and market access projects of many important domestic drug varieties.
These projects included: driving the marketing of Zhejiang Whiteson’s Latamoxef (a broad- spectrum beta-lactam antibiotic); facilitating the rapid sales growth (over three years) of Hainan Tianhuang and its nearly 1 billion RMB in revenues after the overall acquisition; assisting Henan Shuaiguang as it became the second company in China to market Clopidogrel there; participating in the formulation of different dose strengths to achieve a greater market success; and indirectly helping Lepu Medical and Gloria Pharmaceuticals to achieve their goals.
Dr. Wang entered the field of translational research in 2013. He headed the Foshan Industrial Technology Research Institute of the Chinese Academy of Sciences’ pharmaceutical project and established strong commercialization partnerships with the Chinese Academy of Sciences and Peking University.
Dr. Wang holds a degree in Pharmacy from the Peking University Health Science Center and was Vice Chairman of the Student Union at the Center.
Regulatory Specialist, NMPA Regiatration and Approval
With a deep background of 15 years of experience in registering foreign pharmaceutical products for the Asian market, Mr. Bo has assisted in helping many different pharmaceuticals gain entrance into Hong Kong and Taiwan. These include those affiliated with the following conditions: cardiovascular, endocrine, antibiotic, digestive, ED, enteral/parenteral nutrition, psychology, nervous system, monoclonal products, vaccines, hematological tumors, solid tumors, controlled painkillers.
President & CEO
Ms. Shunee Yee is the President and CEO of CSOFT International, a leading global communications and localization company. Responsible for its organic growth from a start-up in a two-bedroom apartment, to becoming an industry leader, Yee oversees CSOFT’s operations across 16 offices and 3 continents.
Throughout her 25+ years of industry experience, Ms. Yee has been featured in a number of publications, including the Boston Globe, the Economist, Fortune Magazine, IDG journals, Investor’s Business Daily and most recently, Forbes Asia. She is one of Fortune’s Top 10 Most Powerful Women in 2012, the recipient of an international Stevie Award for Best Asian Entrepreneur for Women in Business, a Top 25 Globalization Executive by Globalization Today, and was identiﬁed by CNN Money as one of technology’s 36 most powerful disrupters.
Ms. Yee has been recognized for her many contributions in the sphere of education including to the Johns Hopkins US-China Studies Nanjing Center for its cross-cultural program as well as to Michelle Obama’s Let Girls Learn initiative, where CSOFT worked on translating enhanced gender training literature for the Peace Corps from English into multiple languages, helping the Obama Administration reach 62 million girls worldwide.
In June 2016, Ms. Yee led CSOFT into a partnership with the Shenzhen Municipal Government and launched the Shenzhen 100 research report, which assists the government in implementing effective policies to support global market strategies. Ms. Yee sits on Dexter Southﬁeld School’s Academic Board, and she is a Committee member of A Taste of Ginger, an event hosted by the world-renowned Joslin Center, for promoting awareness and education in support of the Asian American Diabetes Initiative.
CSOFT Health Sciences
Li Chenjian is a principal investigator at the IDG McGovern Institute for Brain Research and Associate Dean of the School of Life Sciences at Peking University. His research in neuroscience and drug development has led to significant insights into the mechanisms of neurodegenerative diseases.
CSOFT Health Sciences
Professor Elegant is a physician who joined the pharmaceutical industry after postgraduate training in obstetrics and gynecology in the UK. She has held positions in global drug development, medical affairs, regulatory affairs and drug safety in Japan, Australia, Europe and Asia Pacific. She joined Amgen in October 2016 and is Vice-President, JAPAC Regional Medical Head, based in Hong Kong.
Prior to Amgen, Dr. Elegant was the Vice-President, Regulatory and Medical Affairs, APAC, based in Shanghai for Baxter, and Vice President, Medical Affairs, Asia/ANZ for Baxalta.
Professor Elegant is actively engaged in the training and education of physicians in the healthcare industry. She was involved with establishing the first postgraduate training course for pharmaceutical physicians in Australia. Dr. Elegant is a Fellow of the Faculty of Pharmaceutical Medicine, a member of the FPM International Committee, and is currently working on training programs in the Asia-Pacific region. She is on the Board of Studies for the Masters in Pharmaceutical Medicine, UNSW. She is a founding member of the China Medical Affairs Network. She is on the board of the Medical Affairs Professional Society, and is Adjunct Professor, Faculty of Medicine, University of New South Wales, Sydney Australia.
Professor Elegant is passionate about promoting diversity and inclusion, especially in supporting women leadership. She was involved in Building Talent Edge, a Catalyst Award-winning program supporting women in Baxter Healthcare and leading to a 50:50 men:women ratio at the senior manager level and above across the Asia-Pacific region.
George L. King
Principal Advisor, CSOFT Health Sciences
Dr. George L. King Professor of Ophthalmology, Harvard Medical School Professor of Medicine, Harvard Medical School Director of Research, Senior Vice President, Joslin Diabetes Center Head of the Section on Vascular Cell Biology, Joslin Diabetes Center Founder of the Asian American Diabetes Initiative (AADI)
George L. King, MD is the Director of Research, Senior Vice President, and Head of the Section on Vascular Cell Biology at Joslin Diabetes Center, as well as a Professor of Medicine and Ophthalmology at Harvard Medical School, where he has worked since 1981. Dr. King is the founder of the Asian American Diabetes Initiative, as well as the Medalist Study, which was created in order to discover new protective factors that could prevent the development of diabetic eyes, kidney, nerves. His innovative research has earned many awards throughout his career including the Champalimaud Award, the Cogan Award from the Association for Research and Vision and Ophthalmology, the Edwin Bierman Award from American Diabetes Association, the Alcon Award for Vision Research, and the Annual Award for Excellence in Research from the Japan Society of Diabetic Complications. Additionally, Dr. King was named Honorary Professor and Director of the Fu Dan Institute of Endocrinology and Diabetology at Fu Dan University, Shanghai, China.